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Background: The Dlc1 (deleted in liver cancer 1) tumour suppressor gene codes for a RhoGTPase activating
protein that is found inactivated in many tumour types. Several transcriptional isoforms have been described but
the functional significance and tissue distribution of each form is presently poorly understood. Also, differences in
the number of isoforms and splice variants reported still exist between different mammalian species. In order to
better understand the number and function of the different variants of the Dlc1 gene in the mouse, we have
carried out a detailed analysis. Extensive 3’ RACE experiments were carried out in order to identify all possible Dlc1
isoforms and splice variants in the mouse. In addition, we have generated a gene trapped mouse that targets one
of these isoforms in order to study its biological function. The effect of this gene trap insertion on the splicing of
other isoforms has also been studied.
Results: In addition to the known 6.1 and 6.2 Kb transcripts of Dlc1, our study revealed the existence of a novel 7.6 Kb
transcriptional isoform in the mouse, which corresponds to the human 7.4 Kb (KIAA1723) cDNA transcript. A gene
trapped embryonic cell line, with an insertion between Exon 1 and 2 of the 6.1 Kb transcriptional isoform, was used to
generate a transgenic mouse. This line showed a significant reduction in the expression of the trapped isoform.
However, reduced expression of the other isoforms was not seen. Mice heterozygous for the gene trapped allele were
phenotypically normal, but homozygous mutant embryos did not survive beyond 10.5 days post coitum. Dlc1
gt/gt
embryos showed defects in the brain, heart, and placental blood vessels. Cultured serum-free mouse embryo cells from
Dlc1 deficient embryos had elevated RhoA activity and displayed alterations in the organization of actin filaments and
focal adhesions. The Dlc1 deficient cells also exhibited increased wound closure in an in vitro scratch assay.
Conclusions: The mouse has three major transcriptional isoforms of the Dlc1 gene that are differentially expressed
in various tissues. A mouse with exon 1 of the 6.1 Kb transcript gt resulted in hypomorphic expression of Dlc1
protein and an embryonic lethal phenotype in the homozygous condition, which indicates that this isoform plays
a major role in mouse development. The Dlc1 deficient cells showed altered cytoskeleton structure, increased
RhoA activity and cellular migration.
Background
The Rho family of GTPases control several important
cellular processes, such as cell shape, motility, division
and survival through a series of biochemical networks
[1,2]. RhoGTPases have long been implicated in
tumourigenesis, as Rho activity is found to be increased
in transformed cells and is necessary for the transforma-
tion by the Ras oncogene [3,4]. The Rho proteins act as
molecular switches, cycling between an active GTP
bound state and an inactive GDP-bound state [5]. The
RhoGTPase activating proteins (RhoGAPs) down regu-
late Rho by stimulating its intrinsic GTPase activity [6].
A significant number of RhoGAPs have been shown to
have altered levels in a variety of human tumours and
cell lines [7]. * Correspondence: mmowat@cc.umanitoba.ca
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RhoGTPase activating protein (RhoGAP) that has been
found to be inactivated by deletion or promoter methy-
lation in many tumours, resulting in alterations in cellu-
lar proliferation, cytoskeleton reorganization and gene
expression in tumour cells [8-15]. A recent study using
representational oligonucleotide based microarray analy-
sis showed that heterozygous deletion of Dlc1 occurred
in ~50% of liver, breast and lung tumours and over 70%
of colon cancers [10,16].
The Dlc1 RhoGAP is a multi-domain protein that
contains a sterile alpha motif 2 (SAM2) interaction
domain and a StAR-related lipid-transfer (START)
domain [2,8,17-20]. The Dlc1 gene shows multiple tran-
scription start sites and alternative splicing. In humans,
three major transcriptional isoforms of the Dlc1 gene
has been reported (for a review see [20]). The predomi-
nant 6.3 Kb transcript of Dlc1 encodes a protein of 123
KDa [11]. The existence of proteins for the human
mRNA isoforms of 3.7 Kb (AK025544) and 7.4 Kb
(KIAA1723) have recently been verified by Ko et al.
[21]. In mouse tissues, two principal transcripts of 6.5
and 5.5 Kb and a minor transcript of 7.6 Kb have been
reported by Northern blotting [22], but the complete
characterization and tissue specific expression of all the
isoforms and splice variants of Dlc1 gene in the mouse
has not yet been carried out.
In order to better understand the biological function
of various isoforms of Dlc1, we have generated a mouse
with one of its isoform variants targeted. We have also
characterized the different transcriptional isoforms and
their tissue specific expression in the mouse. The effect
of this gene trap insertion on the other variants has also
been studied.
Results
Identification, characterization and tissue specific
expression of mouse Dlc1 mRNAs and protein
Extensive 3’ RACE experiments were carried out in order
to determine all possible isoforms and splice variants
of the Dlc1 gene in the mouse (Figure 1). Transcripts 1
and 2 correspond to the two previously described tran-
scripts of 6.2 and 6.1 Kb, which agrees with the current
major translated transcripts (isoform-1 and 2, respec-
tively) found in the Vega database (Version 3, 02/06/
2008; Figure 1B). These two transcripts are controlled by
two alternative promoters (Figure 1A). A previously
described 2.8 Kb upstream transcript (AK053142)h a d
not been linked to Dlc1 in the mouse; however, it shows
partial homology to the human Dlc1 7.4 Kb transcript.
We therefore included a primer for this transcript in our
3’ RACE experiments. The regions of homology of tran-
scripts 3 and 4 to the Dlc1 locus are shown in Figure 1B.
These results show a linkage of this upstream 2.8 Kb
transcript with exon 2 of Dlc1, including a novel exon
not previously reported. Based on these complimentary
DNAs (cDNAs) and others, found in the databases, we
predict that there is a 7.6 Kb transcript, which arises
from a promoter greater than 220 Kb upstream from
exon 1 of the 6.2 Kb Dlc1 transcript (Figure 1C). This 7.6
Kb transcript (GenBank accession No. GU1280500, iso-
form-3) contains sequences in common with the pre-
viously reported 2.835 Kb cDNA (AK048960). A second
2.1 Kb transcript (GenBank accession No. GU1280389,
transcript-4) starting from the same promoter retains
160 bp of intronic sequence downstream of exon 3 of the
6.1 Kb transcript (Figure 1B and 1C). In addition, tran-
scripts of 3.4, 2.8 and 1.7 Kb (Nos. 5, 6 and 7) from this
same upstream promoter, that do not link to the Dlc1
gene, were also found (Figure 1B and 1C, GenBank acces-
sion No. GU1280505).
To confirm these transcripts, northern blotting was
carried using a 3.3 Kb ribonucleic acid (RNA) probe
that contained exon 1 to 13 of the 6.1 Kb Dlc1 tran-
script (Figure 2). This probe revealed the existence of
transcripts (7.6, 6.1, 6.2 and 2.1 Kb) in all the tissues
examined. However, the 7.6 Kb splice variant was most
prominent in the liver and placenta and appeared to be
a minor transcript in other tissues.
Real time reverse transcription polymerase chain reac-
tion (RT-PCR) was carried out in order to quantify the
relative expression of the transcripts in various tissues
(Figure 3). These results reveal that the Dlc1 isoforms
are expressed abundantly in all the mouse tissues that
we examined, which agrees with the data observed by
northern blot analysis (Figure 2). However, using real
time RT-PCR analysis, the 6.1 Kb transcript seems to be
expressed highest in the liver, followed by the placenta,
lung, heart, spleen, testis, brain, kidney, thymus and the
skin. The 6.2 and 7.6 splice variants were expressed at
lower levels in the other organs compared with the 6.1
Kb isoform. Liver and placenta appears to predomi-
nantly express the 6.1 and 6.2 Kb transcripts whereas
the 7.6 Kb transcript was predominantly expressed in
lung, heart and placenta based on real-time RT-PCR, in
agreement with the northern blot.
In order to determine the amount of the Dlc1 protein
in different tissues, we carried out western blotting using
a polyclonal anti-Dlc1 antibody that was raised against a
peptide containing amino acids residues 111-370 from
exon 5 of the 6.1/6.2 Kb transcripts (isoforms 1 and 2,
Figure 4). This antibody should pick up proteins trans-
lated from the 6.1, 6.2 and 7.6 Kb transcripts as Exon 5 is
common to all three. The Dlc1 antibody detected a 123
KDa protein presumably derived from the 6.1 Kb tran-
script. The Western blot revealed a very high expression
of 123 KDa Dlc1 protein in the liver, placenta and spleen.
The molecular weight of the Dlc1 protein derived from
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Page 2 of 21the 6.2 Kb transcript is predicted to be 127 KDa. In the
same western blot test we found a band of approximately
127 KDa, which showed a high expression in the thymus,
lung, testis, spleen and liver (Figure 4). Sometimes a
doublet of the 127 KDa band was seen, which suggests a
possible post-translational modification. Further experi-
ments will be needed in order to confirm the identity of
the 127 KDa band and the other cross reacting proteins.
With this antibody, we were not able to detect any pro-
teins in the region of 169.8 KDa - the predicted size of
the protein from the 7.6 Kb transcript (data not shown).
The expression profile of Dlc1 isoforms among different
tissues were correlated, to some extent, with the quanti-
tative PCR and the northern blot.
Methylation status of the alternative promoters of Dlc1
6.1 and 6.2 Kb transcripts
Since the 6.1 and 6.2 Kb transcripts showed differential
tissue expression, we wanted to determine if this was
reflected by differences in promoter methylation. We
used bisulphite treatment of DNA followed by PCR and
pyrosequencing to study the promoter methylation sta-
t u so ft h e6 . 1a n d6 . 2K bt r a n s c r i p t si nv a r i o u st i s s u e s .
For our studies, we targeted five CpG islands located
502 bp upstream of the start codon for the 6.1 Kb tran-
script and four CpG islands located 851 bp upstream of
the start codon of 6.2 Kb transcript (Figure 5A). The
pyrosequencing revealed much lower methylation of the
6.1 Kb promoter region (1-19% mean methylation) in
the 5 CpG islands; the 6.2 Kb promoter region showed
a higher percentage of mean methylation of 60-65% in
all the tissues examined (Figure 5D).
Characterization of the mice heterozygous for the gene
trap allele
Since there were several embryonic stem cell lines avail-
able with exon 1 of the 6.1 Kb transcript gene trapped
(gt), we made a mouse using an embryonic cell line,
Figure 1 Splicing pattern of the transcriptional isoforms of Dlc1 gene. (A) Genomic organization of Dlc1 gene. Solid black rectangles
represent exons of the Dlc1 gene; green rectangles represent exons of the unknown gene (A730069N07Rik). (B) Blast alignment of the 3’RACE
sequences indicating the presence of 7.6 Kb and 2.1 Kb transcriptional isoforms in the UCSC genome database. (C) Predicted isoforms and splice
variants of the Dlc1 gene based on the 3’RACE sequences and cDNAs in the databases. The exonic units are represented by solid rectangles
separated by blank space which indicates an intron.
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Page 3 of 21Figure 2 Northern blot of ribonucleic acid (RNA) from different mouse tissues. Poly(A)
+ RNA from different mouse tissues were transferred
to a nylon membrane and hybridized sequentially with a 3.3 Kb deleted in liver cancer 1 RNA probe and a mouse GAPDH probe.
Figure 3 Absolute quantification of Dlc1 transcriptional isoforms in mouse tissues by real time reverse transcription polymerase chain
reaction (PCR). (A) Representative melt curve analysis plot of the PCR amplified product specific to Dlc1 isoforms and GAPDH. (B) Copies of Dlc1
6.1, 6.2, and 7.6 Kb transcriptional isoforms per 1000 copies of GAPDH (absolute copy number of cDNA). The mean and standard deviation was
determined from triplicate experiments.
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Page 4 of 21named XE082, to assist the functional characterization
of this isoform. We determined the integration site of
the promoter trap plasmid in this line by inverse PCR
and used this information for genotyping the transgenic
mice made with this line (Figure 6). Adult mice hetero-
zygous for the Dlc1 gene trap did not show any gross
physical, histological or behavioural abnormalities. As
well, we have not seen any spontaneous tumours in het-
erozygous mice living to at least 2 years of age.
Multiplex RT-PCR (Figure 7B) and real time RT-PCR
analysis (Figure 8) showed a reduction of the 6.1 Kb tran-
script in the homozygous gt serum free mouse embryonic
cell lines (SFME) compared with wild type and heterozy-
gous lines. The 6.2 and 7.6/2.1 transcripts showed only a
slight reduction, despite the fact that all three transcripts
can be spliced into the bgeo reporter cassette (Figure 7C).
These results indicate that the gene trap’s main effect
resulted in hypomorphic expression the 6.1 Kb isoform.
Figure 4 Dlc1 protein expression in different mouse tissues. Western blots of total cellular protein extracted from different mouse tissues
using Dlc1 polyclonal antibody. The upper blot shows expression of Dlc1 related proteins and the lower blot shows the GAPDH loading control.
Figure 5 Methylation status of the Dlc1 alternative isoform promoters in different mouse tissues.( A )T h eD l c 16 . 1a n d6 . 2i s o f o r m
promoter sequences showing the location of the polymerase chain reaction primers (underlined), sequencing primer (bold and italics) and the
CpG islands (numbered) that were analysed. (B) The reference peak heights for the 6.1 (left) and 6.2 Kb (right) isoform promoter sequences. (C)
Pyrograms for liver DNA, showing the 6.1 Kb isoform promoter (left) and the 6.2 Kb isoform promoter (right). (D) The mean percentage of
methylation for the different CpG islands in the mouse tissues examined, 6.1 Kb promoter (left), 6.2 Kb promoter (right).
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Page 5 of 21Figure 6 Genotyping of the Dlc1 gene trapped mouse. (A)-(i) Diagrammatic representation of the Dlc1 locus showing the insertion site of
the gene trap vector pGT1Lxf; (ii) the gene map of the integrated vector. (B) Sequence of the gene trap vector insertion site with the intronic
junction fragment. The polymerase chain reaction (PCR) primers sequences used to genotype the gene trap mutant mouse are highlighted. (C)
Multiplex PCR showing homozygous, heterozygous and wild type bands in 10.5 dpc Dlc1 embryos.
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Page 6 of 21Figure 7 Multiplex reverse transcriptase polymerase chain reaction (RT-PCR) showing the effect of gene trap insertion on the various
Dlc1 isoforms. (A) Diagrammatic representation of the Dlc1 gene showing the position of different PCR primers sets used; (i) to show relative
expression of GAPDH mRNA and Dlc1 isoforms and (ii) to show the relative expression of gene trap fusion transcripts and Dlc1 normal
transcripts. (B) Multiplex RT-PCR showing the expression of 7.6 Kb, 6.2 Kb and 6.1 Kb Dlc1 isoforms and alternative splice forms relative to
GAPDH expression (C) Multiplex RT-PCR showing the expression of 7.6 Kb, 6.2 Kb and 6.1 Kb Dlc1 isoform normal transcripts relative to their
fusion splice products with bgeo of the gene trap vector.
Figure 8 Quantitative real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis of the absolute copy number of
Dlc1 isoforms in Dlc1 deficient serum-free mouse embryo cell lines. The mean and standard deviation was determined from triplicate
experiments. The upper panel of the diagram shows the position of the RT-PCR primers used for amplification of the specific isoforms. *P <
0.001, by one way ANOVA test.
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gt/gt embryos
No mice homozygous for the gt Dlc1 allele were observed
at birth from heterozygous intercross matings. Histological
analysis of 10.5-11.5 days post coitum (dpc) embryos from
heterozygous matings showed that Dlc1
gt/gt embryos were
necrotic and displayed growth retardation that varied in
severity (Figure 9i). Most of the embryos had a retarded
brain structure and an abnormally enlarged heart (Figure
9 i ) .T h ep r e s e n c eo ft h ebgeo cassette in the gene trap
vector allowed for expression analysis of the Dlc1 gene
after X-gal staining. The anterior neural tube was open
and contorted in the homozygous gene trapped embryos
(Figure 9iii). X-gal stained hearts showed thin and under-
developed atrial and ventricular walls with an apparent
lack of blood cells inside the heart (Figure 10iii).
The homozygous gt mice also showed an absence of blood
vasculature in the yolk sac (Figure 9ii) and in the placental
labyrinth (Figure 10i &10ii). The haematoxylin and eosin
Figure 9 Dlc1
gt/gt embryos. (i) X-gal stained Dlc1
wt/gt and Dlc1
gt/gt embryos and placenta showing expression of Dlc1 exon1-bgeo fusion
protein. (ii) Impairment of yolk sac blood vessel formation in Dlc1
gt/gt mouse embryos. The yolk sacs of 10.5 dpc Dlc1
wt/gt and Dlc1
gt/gt mouse
embryos with the later, showing no detectable blood vessels. (iii) The Dlc1
gt/gt embryos showing failure to close the neural tube at the anterior
part of the body (left: unstained embryos and right: X-gal stained embryos).
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wt/gt placental labyrinths at
10.5 dpc showed sinusoids with maternal enucleated red
blood cells (RBC) and embryonic blood vessels with
nucleated fetal erythrocytes in close proximity with each
other (Figure 10ii). In contrast, the embryonic and placen-
tal vasculature was severely reduced in the Dlc1
gt/gt pla-
centa, as revealed by immunofluorescent staining with the
endothelial and haematopoietic cell marker CD31 (Figure
10i). H&E staining of the Dlc1
gt/gt placenta also showed
aggregates of erythrocytes in collapsed blood vessels (Fig-
ure 10ii). X-gal staining of the 10.5 dpc homozygous gt
embryos revealed a strong expression of the beta-galacto-
sidase fusion protein in the anterior part of the notochord,
somites, liver, heart, lung, forebrain, placenta and tail bud
(Figure 9i &9iii). The defects in placenta and the vitelline
blood vessels are probably the cause for the embryonic
lethal phenotype of the homozygous gene trapped
embryos.
Reduced level of Dlc1protein in a serum free Dlc1
gt/gt
mouse embryos cells
Dlc1 protein expression was determined in serum free
mouse embryo cell lines (SFME) derived from 9.5 dpc
embryos. The homozygous Dlc1
gt/gt SFME cells showed
significantly reduced Dlc1 protein levels (P < 0.001) in
western blots compared with the heterozygous or wild
type cells (Figure 11). We found specific reduction of
the 123 KDa band corresponding to the predicted size
of the 6.1 Kb transcript of Dlc1. There was also an
increase of a cross reacting 127 KDa band in the homo-
zygous gt cells when compared to the wild type and het-
erozygous lines. This protein size corresponds to the
predicted size for the 6.2 Kb transcript.
Dlc1
gt/gt SFME cells showed increased RhoA activity and
an altered cytoskeleton along with increased cell motility
If Dlc1 activity is reduced in the gene trapped cells, one
would expect to see an increase in active Rho activity.
The active Rho levels in the Dlc1 deficient SFME cell
lines were measured by a Rho-GTP pull-down assay.
The Dlc1
gt/gt cells showed a significantly higher (P <
0.001) constitutive level of active GTP bound RhoA
(Figure 12A, B and 12D). The induction of active Rho
following LPA treatment was also significantly higher (P
< 0.001) in the Dlc1
gt/gt cell line compared with the
Dlc1
wt/wt or Dlc1
wt/gt lines. Since RhoA has been impli-
cated in podosome formation in osteoclasts [23] and
dendritic cells [24], we wanted to see if the subcellular
localization of endogenous active RhoA was altered
using an in situ Rho-GTP affinity assay. As in the active
pull down assays, increased levels of active RhoA was
detected by GST-Rho Binding Domain (RBD) protein
staining in the Dlc1
gt/gt cells when compared with the
wild type and heterozygous cells (Figure 12C).
The formation of actin stress fibres and focal adhe-
sions were compared among the various SFME lines
detected by fluorescent conjugated phalloidin and anti-
vinculin antibody staining (Figure 13A, B and 13C). The
Dlc1 gt cells showed a significant increase (P < 0.001) in
actin stress fibre formation and increased vinculin asso-
ciated focal adhesions, when compared with the wild
type and heterozygous cell lines.
It has been previously reported that active RhoA activ-
ity can down regulate p21
WAF1 expression [25]. The
Dlc1
gt/gt cells also showed significantly reduced (P <
0.001) constitutive levels of the p21
WAF1 protein in com-
parison to the cell lines derived from heterozygous and
wild type embryos (Figure 11). We have also found a
positive correlation between reduced expression of Dlc1
and p21
WAF1 in cell lines (R = 0.645; P = 0.004). The
preceding results indicate that the Dlc1 gt cells showed
increased RhoA activity.
Rho proteins are important players in the regulation of
cell motility and reduced expression of Dlc1 enhances
cell migration. In order to study the effect of hypo-
morphic expression of Dlc1 on directed cell migration,
we performed scratch assays by wounding confluent
monolayers of mouse embryonic fibroblast cell lines
derived from wild type, heterozygous and homozygous
embryos. The Dlc1
gt/gt cells showed more rapid wound
closure that was significantly different compared to the
rate of wound closure in wild type and heterozygous
cells (P < 0.001; Figure 14), indicating increased cell
motility. The amount of wound closure decreased
slightly at longer times, possibly due to change in direc-
tion of cell movement.
Discussion
Alternative splicing and promoter usage of genes allows
for an expansion of protein diversity and control. Recent
evidence suggests that 30%-50% of the human and
mouse genes have multiple alternative promoters [26].
In humans, at least three transcriptional isoforms (6.3,
3.7 and 7.4 Kb length) of Dlc1 gene have been identified
that are expressed under the influence of three alterna-
tive promoters spanning approximately 400 Kb. The
mouse Dlc1 gene on chromosome 8B1 and the human
gene on 8P22 have an almost identical exon/intron
structure, except for the presence of an extra codon in
exon 5 of the mouse [22,27]. In a previous study using
5’ RACE and northern blotting analysis, Durkin et al.
reported the presence of 3 Dlc1 transcripts in the
mouse of 5.5, 6.5 and 7.5 Kb in length [22]. However, in
our study using extensive 3’ RACE and northern blot
analysis, we have found four major transcriptional iso-
forms of Dlc1 (2.1, 6.1, 6.2 and 7.6 Kb). The complete
characterization of the 7.6 Kb and 2.1 Kb transcripts
lead to the identification of a novel exon of 34 bp in
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Page 9 of 21Figure 10 Placental and heart abnormalities in Dlc1
gt/gt embryos. (i) Immunofluorescent staining of the placenta of 10.5 days post coitum
(dpc) Dlc1
wt/wt and Dlc1
gt/gt embryos with PECAM (CD31) antibody. Twelve micrometer thick frozen paraformaldehyde fixed placental sections
were incubated with anti-PECAM-1 antibody and then with FITC conjugated secondary antibody. (ii) The yellow arrow indicates a continuous
network of blood vessel in the placental labyrinth haematoxylin and eosin stained sections of placental labyrinth of 10.5 dpc Dlc1
wt/gt and
Dlc1
gt/gt embryos. Black asterisks indicate fetal erythrocytes and the yellow asterisk indicates maternal red blood cells. (iii) Transverse section of
the X-gal stained heart of 10.5 dpc Dlc1
wt/gt and Dlc
gt/gt embryos. The yellow asterisk indicates normal thick trabeculated ventricular wall; the red
asterisk thin smooth atria wall; and the green asterisk with foetal erythrocytes.
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2 to an additional 1.7 Kb of exon sequences, resulting in
the 7.6 Kb fusion transcript. The upstream 1.7 Kb exon
sequences were generated from a previously uncharac-
terized gene 5’ of Dlc-1 (A730069N07Rik). It is interest-
ing to note that comparison of the mouse 7.6 Kb
mRNA with the human 7.5 Kb transcript revealed that
the 5
th exon is exactly 34 bp in length and only differs
in its relative position within the intronic sequences.
The conserved nature of this novel exon sequence sup-
ports a functional significance for the 7.6 Kb mRNA.
The human 7.4 Kb, KIA1723, cDNA has the potential
to encode for a 1528 amino acid protein [28]. Recently
Ko et al. have shown high expression of a greater than
150 KD protein in the human heart tissue using an anti-
body based on this cDNA sequence [21]. The putative
Figure 11 Dlc1 and p21
WAF1 protein expression in Dlc1
wt/wt, Dlc1
wt/gt, and Dlc1
gt/gt SFME cell lines. Western blots of total cellular protein
extracted from different serum-free mouse embryo (SFME) cell lines. (A) Upper blot shows the expression of Dlc1 protein and lower blot shows
actin expression. (B) Upper blot shows the expression of p21
WAF1 protein and the lower blot shows actin expression. (C) Plot showing the
relative intensity of Dlc1 123 KDa protein and p21
WAF1 protein in SEME cell lines. Means and standard error of mean determined from at least six
independent experiments using cell lines derived from different mouse embryos are given. * P < 0.001, by one way ANOVA test.
Figure 12 RhoGTP pull down assay and in situ RhoGTP affinity assay. RhoGTP pull down assay showing (A) constitutive and (B) LPA
induced and control levels of active RhoGTP in Dlc1
wt/wt, Dlc1
wt/gt and Dlc1
gt/gt SFME cell lines. (C) Dlc1 SFME cells exponentially growing on
glass slides were fixed and cells were incubated with 50 μg/mL of soluble GST (i) or GST-RBD (ii). RhoGTP-bound RBD was detected by GST
immunostaining. (D) Plot showing the RhoGTP to total Rho protein by scanning the relative intensity of the protein bands in non-treated and
LPA induced in SEME cell lines. Means and standard error of mean determined from at least six independent experiments using cell lines
derived from different mouse embryos are given. *P < 0.001, by two way ANOVA test.
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Page 11 of 21promoter region of both the human and mouse Dlc1 7.6
Kb mRNA is approximately 400 Kb upstream of the
exon 2 of the Dlc1 6.2 Kb transcript. Shorter transcripts
originating from this promoter are also found, which do
not encode Dlc1 RhoGAP related sequences. The exis-
tence of this larger Dlc1 polypeptide has not yet been
verified in the mouse and we have not yet seen a pro-
tein of this size on our western blots. The mouse 2.1 Kb
transcript retains only exon 2 and 3 of the regular Dlc1
transcripts and would not encode a RhoGAP related
protein. Understanding the function of these shorter
transcripts will have to await specific knockout mouse
models. Analysis of the nucleotide sequence of the three
isoforms reveals that these isoforms have a conserved
domain structure and that they may be functionally
redundant. However, these isoforms were not sufficient
to rescue the embryonic lethal phenotype of our homo-
zygous gt mice.
T h eg e n ef u s i o n so b s e r v e di nt h e7 . 6 / 2 . 1K bt r a n -
scripts may be due to the bypassing of 3’ end formation
sites that has been observed for other genes in the Fan-
tom database [29]. Exon 4 of the A730069N07Rik tran-
script contains two successive polyadenylation signals
TGTTTT and AATAAA, which are considered weak in
comparison to the presence of three successive polyade-
nylation signals (AATAAA, ATTAAA, and TGTTTT)
Figure 13 Altered cytoskeletal organization in Dlc1 gene trapped and normal serum-free mouse embryo (SFME) cell lines. (A) SFME cell
lines were stained with phalloidin-TRITC and DAPI. (B) Localization of vinculin in SFME cell lines by immunofluoresence. Cells were also stained
with DAPI. (C) Cells were analysed to determine total cell area and the numbers of focal adhesions and stress fibres present as outlined in
materials and methods. Means and standard error of mean determined from at least six independent experiments are given. *P < 0.001, by one
way ANOVA test.
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Page 12 of 21Figure 14 Scratch assay of Dlc1 gene trapped and normal mouse embryonic fibroblast cell lines at various time points.( A )T h e
homozygous Dlc1
gt/gt cells show increased wound closure by 18 h compared with the Dlc1
wt/wt and Dlc1
wt/gt cell lines. (B) Scratch assays at
different time points. The plots show the changes in wounded surface area after 6 h [Blue] and 18 h [Red] after the wound creation. Mean ±
standard error of mean of three independent experiments for each cell type and eight areas imaged for each experiment, *P < 0.001, by one
way ANOVA test.
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Page 13 of 21[30] present in the 14th exon of regular Dlc1 transcripts.
The weak polyadenylation signal may be responsible for
bypassing the 3’ end formation and lead to the forma-
tion of a fusion transcript between the genes. However,
the conserved nature of the exon 5 of the 7.6 transcript
contradicts this finding and further study is necessary in
order to validate these observations.
The 6.1 Kb Dlc1 transcript is predicted to encode a
123 KDa protein, which is highly expressed in the fore-
brain, anterior tip of the notochord, somites, liver, heart
and placenta, suggesting an important role for this Dlc1
isoform in the development of theses organs. The 6.2
Kb alternative transcript contains a novel first exon
located 133 Kb upstream of exon 2 and potentially
codes for a 127 KDa protein. The first exon of the 6.2
K bt r a n s c r i p ts u b s t i t u t e s4 7a ao ft h ef i r s t1 3a ao ft h e
6.1 Kb Dlc1 transcript. The existence of the 127 KDa
Dlc1 protein has not yet been fully validated. However,
in our western blots, using an antibody raised against a
peptide to exon 5, we identified a band equivalent to
127 KDa. The expression level of 127 KDa Dlc1 protein
showed tissue specific differences from the 123 KDa
protein. For example, testes showed expression of the
127 KDa band and reduced levels of the 123 KDa band
(Figures 3 and 4). There is possibility that the 127 KDa
protein is a cross reacting non-specific protein. How-
ever, we argue that the 127 KDa band is the protein
product of the 6.2 Kb isoform because of its molecular
weight, which almost exactly matches the predicted pro-
tein product of 6.2 Kb isoform. Another reason for such
an argument is that the 127 KDa protein band has
increased intensity in the Dlc1
gt/gt cell line as opposed
to the wild type or heterozygous cell lines. This may be
explained as a cellular response to complement the
reduced level of 6.1 Kb transcript in the gt cells or an
effect of the relative abundance of 6.2 kb isoform. The
6.1 and 6.2 Kb Dlc1 isoforms may be functionally
redundant because of their structural resemblance and,
thus, could complement each other. Recently, such
functional redundancy has been shown by Ko et al.i na
study using Myc tagged Dlc1 isoforms expressed in
hepatoma cell lines [21]. They showed that human Dlc1
isoforms a and b (equivalent to mouse isoforms 1 and
3) could suppress stress fibre formation in vitro.H o w -
ever, further experimentation is necessary in order to
test such a claim.
The N terminus of Dlc1 protein contains a sterile
alpha motif (SAM)2 interaction domain, amino acids
13-64 in the 6.1 Kb and 47-98 in the 6.2 Kb transcripts.
The SAM domain is a motif that occurs in many tran-
scription factors and signalling proteins [19]. The 123
and 127 KDa Dlc1 proteins differ in exon 1, which is a
short stretch of amino acids upstream of the SAM2
domain. Deletion of the SAM domain increases the
velocity of cell migration but reduces directionality by
acting as a negative regulator of Dlc1RhoGAP activity
[31]. A truncated version of Dlc1 protein that contains
the N terminal domain, but not the GAP domain, loca-
lizes to focal adhesions and can act as a dominant nega-
tive protein [32]. Recently, in hamster kidney cells,
co-localization of Dlc1 protein with Caveolin-1 in focal
adhesions was found to be independent of the SAM
domain [33]. However, the Dlc1 SAM2 domain has
been shown to interact with the elongation factor
EF1A1, targeting it to the membrane periphery and
membrane ruffles [34].
It is possible that exon 1 of the Dlc1 isoforms may
interact with different proteins or allow different subcel-
lular localization for the spatial regulation of cell move-
ment. In that case, the 6.1 Kb and 6.2 Kb isoforms may
not be able to rescue each other’s RhoGAP activity due
to different interacting partners or subcellular localiza-
tion. Alternatively, the two isoforms may have different
temporal or tissue specific expression during develop-
ment, a theory which is supported by our results.
Experiments that will test these possibilities are ongoing.
The mean frequency of the promoter methylation for
the Dlc1 isoforms helps to explain the tissue expression
pattern. The promoter of the 6.1 Kb transcript showed a
significantly lower mean percentage of CpG methylation
(1%-19%) compared with the promoter of 6.2 Kb tran-
script (62%-65%). Hypermethylation of the Dlc1 promo-
ter is a common mechanism for transcriptional
repression of the Dlc1 gene in several human malignan-
cies and hypermethylation of the 6.1 Kb transcript pro-
moter is usually found in human tumours [9,14].
The gene trap insertion occurred within intron 1 of
the Dlc1 6.1 Kb transcript and this allowed us to exam-
ine the functional significance of the specific loss of this
transcript. The gene trap vector inserted in the Dlc1
locus should delete the majority of the downstream cod-
ing sequences if obligatory cleavage and polyadenylation
at the SV40 polyadenylation signal of the gene trap con-
struct occurs. By multiplex PCR, we showed the exis-
tence of fusion transcripts for all three of the Dlc
isoforms spliced to the bgeo coding region. However,
only the 6.1 Kb transcript was significantly reduced,
resulting in the hypomorphic expression of the 123 KDa
protein and subsequent phenotypic abnormalities in the
mouse. The hypomorphic expression was presumably
due to low level splicing around the gene trap plasmid
insert. There is a possibility that the phenotypic
abnormalities in our study could be due to the disrup-
tion or deletion of a microRNA expressed from this
intron [35]. However, we have not found any evidence
of any known microRNAs anywhere near or within this
intron of Dlc1 in the miRBASE database, as well as any
computationally identified candidate microRNA genes
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Dlc1 exon 5 knockout mouse of Durkin et al.[ 3 8 ] .
These results suggest that the gt ES cell libraries maybe
a useful resource for studying specific knockdown of
transcriptional isoforms and splice variants of genes.
The Dlc1 gene plays a critical role in regulating cellu-
lar functions during earlym u r i n ed e v e l o p m e n t .T h e
abnormalities found in the Dlc1 gt embryos are a com-
mon occurrence in mouse gene knockouts that result in
death at the early stages of embryogenesis, due to organ
systems failure [38,39] and are often associated with car-
diac or placental defects [38]. The abnormally enlarged
heart, lack of yolk sac blood vessels and underdeveloped
blood capillaries in the placental labyrinth of the homo-
zygous Dlc1 gt embryos appeared at a developmental
stage when the Dlc1 transcripts are normally expressed
and, most probably, caused the embryonic lethality.
Whether the heart and brain defects are a direct result
of Dlc1 loss or a consequence of the lack of placental
blood vessel formation will have to await the isolation of
conditional Dlc1 knockout mice.
Previously, it has been shown that targeted disruption
of mouse Rho associated coiled coil kinase-2 (ROCK-II)
gene resulted in intrauterine growth retardation and
defective branching morphogenesis of the placental
labyrinth [40]. The ROCK-II mRNA has been found to
be expressed abundantly in placenta [41]. The active
form of RhoA binds to ROCK kinase, which phosphory-
lates myosin phosphatase, resulting in increased myosin
light chain (MLC) phosphorylation allowing contraction
[41]. The Rho/ROCK signalling pathway also contributes
to the Ca
2+ sensitization of smooth muscle contraction
[42]. RhoA is abundantly expressed in vascular smooth
muscle and its activation increases vascular tone, result-
ing in increased permeability [43]. Rho GTPases has long
been implicated in the regulation of endothelial perme-
ability [44]. Recently, it has been shown that increased
expression of constitutively active RhoA induced cell
rounding and apoptosis of endothelial cells [45]. There-
f o r e ,i ti sp o s s i b l et h a tD l c 1p r o t e i np l a y sas i g n i f i c a n t
role in placental and heart development due to its regula-
tory effect on Rho/ROCK signalling pathway.
The Dlc1 protein has been reported to be localized to
the focal adhesions as shown by colocalization with the
focal adhesion protein vinculin [46]. Focal adhesions are
a structural link between the actin cytoskeleton and the
extracellular matrix and are regions of signal transduc-
tion that can regulate growth control [47-49]. We have
shown that the formation of actin stress fibres and vincu-
lin rich focal adhesions were significantly increased in the
hypomorphic Dlc1
gt/gt SFME and fibroblast cell lines.
Dlc1 has been implicated in the phosphoinositide and
RhoGTPase signalling pathways, both of which can regu-
late stress fibre formation and focal adhesions assembly
[50-52]. Similar findings have been reported by Holeiter
et al. in breast cancer cells using siRNA mediated knock-
down of Dlc1 transcripts [53] and Xue et al.i ne m b r y o -
nic liver progenitor cells using shRNA [10]. In contrast
to our results, Durkin et al. reported that their knockout
mice showed reduced actin stress fibre and vinculin rich
focal adhesions in their Dlc1
-/- mouse embryonic fibro-
blast (MEF) cells [38]. A possible reason for this may be
that the culturing of our SFME cells on fibronectin
coated plates, may stimulate the Rho signalling allowing
the formation of stress fibres. Using soluble GST-RBD in
order to detect endogenous RhoGTP, we have been able
to show that the Dlc1
gt/gt cells exhibit increased RhoA
activity and subcellular localization of active RhoA at the
focal adhesions. Similar findings have been previously
reported by Berdeaux et al. in nontransformed fibroblasts
[54]. Rho proteins are important regulators of cellular
migration [55]. In addition to the cytoskeletal changes,
the Dlc1
gt/gt MEF cells showed significantly increased cel-
lular migration in wound closure assays compared with
the heterozygous or wild type MEFs. Similarly, Holeiter
et al. found rapid wound closure in scratch assays using
RNAi to knockdown Dlc1 in MCF7 breast cancer cells
[53]. The cellular migration rate decreased as the cells
approached to the midline of the wound from both sides,
which might be because of changes in the direction of
migration due to contact or the depletion of nutrients in
the media. All of this evidence is consistent with the sug-
gestion that Dlc1 deficiencym a yb ead r i v i n gf o r c ef o r
cellular migration by remodelling the actin cytoskeleton
and focal adhesions.
Recently, it has been shown that in H-Ras oncogene
transformed fibroblasts, RhoA may cooperate in trans-
formation by suppressing the cell cycle inhibitor
p21
WAF1 that is induced by the sustained activation of
the ERK-MAP kinase pathway [3,25]. In our study, we
saw increased RhoA activity and a reduced level of con-
stitutive p21
WAF1 expression in the Dlc1
gt/gt SFME cells.
The reduced expression of Dlc1 and p21
WAF1 in the
Dlc1 deficient cell lines was positively correlated. It is
possible that activation of the Rho pathway through
mutation of the Dlc RhoGAPs will complement the Ras
oncogene in cell transformation in vivo.
Conclusions
We have found that the Dlc1 gene has four transcrip-
tional isoforms expressed under the influence of three
alternative promoters. The alternative promoters are dif-
ferentially methylated in mouse tissues and this relates
to the differential expression of the proteins in the tis-
sues examined. We also identified a 127 KDa Dlc1 pro-
tein that may originate from the 6.2 Kb alternative
transcript. We generated a Dlc1 gt mouse that resulted
in hympomorphic expression of the 6.1 Kb transcript
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Dlc1
gt/gt mouse embryos showed significant abnormal-
ities in yolk sac and placental labyrinth vasculature sug-
gesting an important developmental role for the 6.1 Kb
isoform of Dlc1 during early embryonic development. A
deficiency of this isoform resulted in increased GTP-
Rho levels resulting in more stress fibre and vinculin
associated focal adhesion formation. This in turn
resulted in heightened cellular mobility.
Methods
Generation of Dlc1 mutant mice
An ES cell line (XE082) containing a gene trap insertion
in the 1st intron of the Dlc1 locus (Figure 6A) was
obtained from Bay Genomics (CA, USA). The gene trap
plasmid pGT1Lxf contains the Engrailed-2 (En2) splice
acceptor sequence upstream of the b-geo reporter gene,
followed by SV40 polyA sequence. XE082 ES cells were
injected into C57BL/6 blastocysts and the resulting chi-
meric mice were backcrossed to C57BL/6 to test for
germ line transmission. One chimeric male mouse
transmitted the Dlc1 gene trap allele through his germ
line and was used in the subsequent studies.
We utilized an inverse PCR technique to localize the
insertion site of gene trap vector (GenBank accession No:
GS598775 (Figure 6A) [56]. Genomic DNA was digested
with MseI, circularized with T4 DNA ligase and PCR
amplified with a pair of diverging primers (Figure 6A/i-ii).
This amplicon was then sequenced and indicated that
the plasmid had integrated into the intron 1 of Dlc1 gene
(Figure 6B). Based on the integration information, we
designed: (1) a primer in the neomycin-resistance cassette
of pGT1Lxf (5’-GATTCCACCGCCGCCTTCTATG); and
(2) two intronic primers encompassing the integration
point (5’-GTGTAAGTTTGCCTCCTCCTTTGG and 5’
TCCTGCTGGTGTGTGTAAACAGAC). These three pri-
mers, when used in multiplex PCR, amplify a 570 bp pro-
duct specific for the targeted allele and a 388 bp band for
t h ew i l dt y p eg e n e( F i g u r e
Histological analysis and X-gal staining of the mutant
embryos
Embryos from heterozygous crosses were dissected at
10.5 and 11.5 dpc and yolk sacs were used for DNA
extraction and subsequent genotyping. Placentae were
fixed in 10% neutral buffered formalin and sections
were stained with H&E for microscopic examination.
We isolated 10.5-11.5 dpc embryos from heterozygous
crossings and they were fixed and stained as a whole
mount in X gal as described [57].
SFME cell cultures
Embryos from heterozygous intercross matings were
harvested on 9.5 dpc, cells were dissociated by
trypsinization and culturedi ns e r u m - f r e ec o n d i t i o n s
which consists of epidermal growth factor, transferrin,
high density lipoprotein, insulin and fibronectin coated
plates [58]. Cells grow under these conditions do not
senesce and have normal karyotypes. For MEF cultures,
9.5 dpc embryos were cultured in Alpha MEM (Gibco,
Invitrogen, ON, Canada) supplemented with 10% fetal
bovine serum and antibiotics. Cells were genotyped by
PCR and studies were performed on wild type (Dlc
wt/wt),
heterozygous (Dlc1
wt/gt) and homozygous (Dlc1
gt/gt) cells
prior to passage 10. All cell line specific experiments
were repeated with multiple cell lines of each type
obtained independently from different mouse litters.
Western blotting and Immunohistochemistry
SFME as well as MEFs cells were grown on 150 mm
plates until confluent, washed with ice-cold phosphate-
buffered saline (PBS) and then lysed with radioimmuno-
preciptation assay buffer (150 mM sodium chloride, 1%
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulphate (SDS), 50 mM Tris, pH 8.0) supplemented with
1× protease inhibitor cocktail (S8820, Sigma, MO, USA).
After sonication for 3× 5 s on ice, the cell lysates were
clarified by centrifugation at 12,000 rpm in a Hettich-
Mikro 20 centrifuge at 4°C. The protein concentration
was estimated by Bicinchoninic acid protein assay kit
(BCA1 and B9643, Sigma) according to the manufac-
turer’s instructions. Twenty micrograms of total protein
was separated on 8% SDS-polyacrylamide gel and trans-
ferred to a polyvinylidene fluoride microporous (PVDF)
membrane (IPVHO9120, Millipore Corp, MA, USA).
The membrane was then blocked for 1 h in 5%
skimmed milk powder in TBST buffer (20 mM tris, 137
mM NaCl, 0.1% tween) and hybridized with Dlc-1 anti-
body (Sc32931, Santa Cruz Biotechnology, CA, USA;
1:500 dilution) over night. After washing in TBST buf-
fer, the membrane was incubated with secondary horse-
radish peroxidase-conjugated anti-Rabbit antibody
(1:2000 dilution; #7074, Cell Signaling Technology, MA,
USA) for 1 h at room temperature. Immunoreactivity
was detected using enhanced chemiluminescence
(RPN2132, GE Healthcare, NJ, USA). The membrane
was then stripped with 0.1 M NaOH and blotted again
with anti-Actin or GAPDH antibody (A2006, Sigma,
1:1000 dilution). The western blots were scanned using
a Storm 840 PhosphorImager scanner and quantified by
densitometry using ImageQuant software (version 1.2;
both from Molecular Dynamics, Inc, CA, USA).
Subconfluent cultures of different cell types were pla-
ted on fibronectin coated glass coverslips and were incu-
bated for 12 h in serum-free medium prior to fixation
with 2% neutral buffered formalin. Staining of actin
fibres with TRITC labelled phalloidin (P1951, Sigma)
was performed according the manufacturers’ protocol.
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escence using monoclonal anti-Vinculin-FITC antibody
(F7053, Sigma). The preparations were examined on
Axioplan 2 microscope (Carl Zeiss, Inc, ON, Canada)
and an AxioCam HR charge-coupled device (Carl Zeiss).
A 63×/1.4 oil objective lens (Carl Zeiss) was used at
acquisition times of 200-300 ms for FITC (focal adhe-
sions) 100-150 ms for TRITC (actin fibres), and 20 - 50
ms for DAPI (nuclei).
For stress fibre and focal adhesion quantification, six
high resolution Z stacks images of phalloidin and anti-
vinculin stained cells were taken at 1 μmi n t e r v a l sa n d
projected as a single image after deconvolution
using Axiovision 3.1 software (Zeiss). The deconvoluted
flattened image was then analysed using ImageJ 1.38×
public domain software. The stress fibre and focal adhe-
sion frequency was calculated as described by Stachan
et al. [59].
Rho activation and in situ Rho GTP affinity assay
Rho activity in wild type, heterozygous and homozygous
cell lines were analysed using the active Rho-GTP pull
down assay. A plasmid expressing GST-Rhotekin Rho-
binding domain peptide (kindly provided by Dr Alan
Hall, Sloan-Kettering Institute, New York, USA) was
transformed into BL21 cells and expression was induced
with 0.5 mM isopropyl b-D-1 thiogalactopyranoside for
2 h at 37°C. GST fusion proteins were purified on glu-
tathione-Sepharose 4B beads (GE Healthcare Bio-
Sciences Inc, Quebec, Canada).
SFME cells were grown in 150 mm dishes and were
then deprived of growth factors for 12 h followed by
addition of lysophosphatidic acid (LPA, 20 ng/mL) for
30 min. At the end of the treatment, cells were rinsed
with ice-cold PBS and 500 μL of lysate buffer was added
to each dish. Cells were scraped, and cell lysates were
clarified at 10,000 × g for 10 min. Pull-down assays
were performed according to Ren and Schwartz [60]
with 30-40 μg of GST-fusion protein and 800-1500 μg
of protein lysate per sample.
In situ detection of active Rho was performed as
described by Berdeaux et al. [54,61]. Cells growing on
glass coverslips were briefly washed in PBS and immedi-
ately fixed with freshly prepared 4% paraformaldehyde
(PFA) in PBS for 10 min at 4°C. After 30-min of incuba-
tion in PBS containing 3% BSA, 0.1 M glycine, and
0.05% Triton X-100 followed by incubation with the
soluble GST-RBD (30 μg/ml) or GST (reduced) for 2 h
at 4°C, the samples were washed three times and incu-
bated with an anti-GST monoclonal antibody (1:1000
dilution) in wash buffer for 1 h at room temperature.
The signal was detected by incubation with FITC conju-
gated anti-rabbit IgG (1:1000 dilution) for 45 min at
room temperature. Samples were mounted in antifade
reagent containing DAPI.
RNA isolation and cDNA preparation
RNA was isolated from different tissues of C57BL/6J
mouse, as well as SFME cell lines using TRIzol Reagent
(Invitrogen Inc, ON, Canada) according to the manufac-
turer’s instructions. Total RNA (5 μg) was reversed tran-
scribed using SuperScript II Reverse transcriptase
(Invitrogen) and random hexamers (Invitrogen).
3’rapid amplification of cDNA ends (RACE) analysis
The 3’RACE were carried out using DNase treated total
RNA extracted from the cerebellum of 12.5 dpc embryo,
placenta, adult brain and heart of C57BL/6J mice. First
strand cDNA synthesis for 3’ end was performed using
50 ng of the oligonucleotide dT Primer (Table 1), 5 μg
of total RNA and SuperScript II reverse transcriptase
(Invitrogen) following the manufacturer’s protocol [62].
The 3’end was then amplified using a primer that con-
tains part of the oligonucleotide dT primer, which binds
to these cDNAs at their 3’ ends, and exon specific pri-
mers from the Dlc1 gene (Table 1). A second amplifica-
tion series was then performed using internal nested
primers (Table 1) to suppress the amplification of non-
specific products.
All 3’RACE reactions were electrophoresed through
1.5% agarose gels and visualized. 3’RACE products were
excised from the agarose gel, purified using Qiagen gel
extraction kit (Qiagen Inc, ON, Canada) and cloned into
the pGEM-T Easy Vector Systems (Promega Fisher Scien-
tific, ON, Canada) using the manufacturer’s instructions.
After cloning 3’RACE products, both strands of DNA
were sequenced for each construct. Sequencing was per-
formed by the DNA Sequencing facility at Manitoba
Institute of Cell Biology using BIG DYE terminators
from Applied Biosystems, Inc (PE Applied Biosystems,
ON, Canada) and sequencing reactions were run on ABI
310 DNA Sequencer.
Northern blot analysis of DLC-1 mRNA
Poly(A)
+ RNA was prepared from different tissues of
C57BL/6J mice and SFME cell lines using mRNA isolation
kit (Roche Diagnostics, Quebec, Canada) and analysed by
Northern blot hybridization using 2.2% (w/v) acrylamide-
0.5% (w/v) agarose gel [63]. The blot was probed with a
32P-labelled 3.3 Kb RNA probe generated from Dlc1 6.1
Kb isoform. The 3.3 Kb probe was generated by nested
PCR primers (Table 1) and cloned into the Xho1 restric-
tion site of Litmas28i vector (New England BioLabs, MA,
USA) containing T7 promoter on both sides. The vector
was linearized and the radiolabelled antisense RNA probe
was generated using T7 polymerase.
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multiplex PCR
The relative expression of the different transcriptional var-
iants was determined by quantitative real time and multi-
plex RT-PCR. Three forward primers were designed, one
primer each from the exon 1 of 6.1 and 6.2 Kb transcripts
and the third primer designed from the exon 4 of 7.6 Kb
transcript, which is also common to 2.1 Kb transcript. The
6.1 and 6.2 Kb transcript specific forward primers were
combined with a reverse primer designed from exon 2 and
the 7.6 Kb transcript specific forward primer was com-
bined with a reverse primer specific to exon 4 of 6.1 Kb
transcript, respectively. PCR primers were designed using
t h eG e n eF i s h e r - v e r s i o n2s o f t ware (Bielefeld University
Bioinformatics Service, Bielefeld, Germany) for quantifica-
tion of the various isoform variants (listed in Table 1).
Absolute quantification of the transcripts was performed
in an iCyclerIQ (Biorad, ON, Canada). Each reaction mix
contained SYBR Green (Sigma S9430), Fluorescein calibra-
tion dye (Biorad, 170-8780) and 200 nM of each primer,
Table 1 List of primers used for 3’RACE, real time polymerase chain reaction (PCR), multiplex PCR, genotyping, and
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Primers for Northern probe
1st round PCR CTGCGCCGACCTTAATGTGTAG GTTGCAGTCACGGGTGCTTC
2nd round PCR CTCGAGCTGCGCCGACCTTAATGTGTAG GTCGACGTTGCAGTCACGGGTGCTTC
Primers for real time quantification of splice variants
7.6 Kb transcript TCCACCGATCCATCATCCACTC CGGTGAGGACTGATCTCCAGCTTCATG
6.2 Kb transcript TCCTTCAGCGACCACATCAGAG
GACTGGTTTCCCCCAGTATGCA
6.1 Kb transcript CGCCGACCTTAATGTGTAGAGAC
2.1 Kb transcript TCCACCGATCCATCATCCACTC GCCCACTGAGTGCTGAGACTG
AAGTAC
GAPDH TTC CGT GTT CCT ACC CCC AAT GTGT GGAGTTGCTGTTGAAGTCGCAGGAG
Primers for methylation study
6.1 Kb Transcript Biotin-
GTAAGAAAAGGTAGAGGGGAAATTGAGTA
CTCCTTCCCCCTTTCCTAAAATAT TTTTCCCAAAATCTACACT
6.2 Kb transcript TAGGAGGTTAGTATGGGTTGTA Biotin-
AAACCTAATACTAACATAAAACAATATC
AAATTGTTTTTTTGATTTTAA
Multiplex PCR primers for genotyping Dlc1 gene trap embryos
TCCTGCTGGTGTGTGTAAACAGAC GTGTAAGTTTGCCTCCTCCTTTGG
GATTCCACCGCCGCCTTCTATG TCAAGCAAAAAGGTCTCGTATGTTGTG
Multiplex PCR primers for fusion transcripts
(7.6+2.1)Kb transcript TCCACCGATCCATCATCCACTC
ACGACGACAGTATCGGCCTCAG
6.2 Kb transcript TCCTTCAGCGACCACATCAGAG
6.1 Kb transcript CGCCGACCTTAATGTGTAGAGAC
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Page 18 of 21200 nM dNTP solutions, 1 × Reaction buffer, 1.5 mM
MgCl2 and 0.5 U Taq polymerase. The thermal cycling
conditions were: 95°C for 1 min, 40 cycles of 95°C for 15 s,
62°-65°C for 30 s and 72°C for 30 s. In order to determine
the absolute copy number of target transcripts, Dlc1 iso-
forms (6.1, 6.2 and 7.6 Kb) and GAPDH cDNAs were
amplified using specific primer sets as described in Table
1. The purified PCR products were cloned in pGEM-T
easy vector system and the plasmid DNA was used to gen-
erate calibration curves, which also permitted evaluation
of PCR efficiencies using the formula E =1 0
[-1/slope].T h e
efficiency of amplification was checked for all targets by
performing a series of serial dilutions of template for each
primer pair in triplicate. Real time PCR data quality con-
trol calculations were run on the SAS program as
described [64,65]. The E value varied from -2.05 to -3.4
which represents an acceptable PCR efficiency between
90%-95% [66]. Quantitative RT- PCRs were then con-
ducted for different mouse tissue samples, and the specifi-
city of each amplified product was confirmed by the
melting curve analysis (Figure 3A). Results were expressed
as copy number of specific isoforms per 1000 copies of
GAPDH cDNA (Figure 3B).
For multiplex PCR, we used two different strategies.
First, the different isoforms were quantified relative to
GAPDH internal standard and second, all the splice var-
iants were quantified to the corresponding fusion tran-
script that was generated by fusion to the bgeo gene,
which is part of the gene trap insertion. Relative expres-
sion of cDNA equivalent of 400 ng total RNA was quan-
tified using two sets of primers in the same PCR reaction;
one set specific to the Dlc1 isoform and the other set spe-
cific to either the GAPDH gene or to the bgeo fusion
cDNA. The PCR products were run in a 1.5% agarose gel
and stained with ethidium bromide for visualization.
In vitro scratch assay
Cell migration rates of wild type, heterozygous and
homozygous cell lines were compared by an in vitro
scratch assay [67]. Prior to the migration experiments, 60
mm cell culture plates were incubated for 4 h with 10
mg/mL fibronectin in Alpha-MEM. Coated dishes were
blocked with 3 mL of 2 mg/mL bovine serum albumin
(BSA) for 1 h at 37°C. Then, excess fibronectin was
removed by washing with PBS and dishes were refilled
with 3-5 mL of media before plating the cells. The wild
type, heterozygous and homozygous fibroblast batches
were seeded onto the fibronectin coated plates and cul-
tured until confluent. After reaching confluency, the cell
monolayer was scratched with a p200 pipette tip in two
diagonal lines. The cell debris was removed and the edge
of the scratch was smoothened by washing the cells once
with 1 mL of the growth medium and then replaced with
5 mL of medium and incubated at 37°C for 18 h. In order
to obtain the same field during the image acquisition,
reference points were created by marking the underneath
of the dish with a fine pointed marker using a stereo-
microscope. Subsequent photographs of the scratches
were taken at 0, 6 and 18 h time intervals using a phase
contrast microscope. We quantified the cell migration
rate by determining the total area that the MEF cells
moved from the edge of the scratch toward the center of
the scratch during 0-6 h and 6-18 h of incubation follow-
ing the creation of the wound in terms of pixels calcu-
lated manually using the Image J 1.38× public domain
software (available at http://rsb.info.nih.gov/ij/).
Methylation study of the Dlc1 promoter region
Chromosomal DNA was isolated from different mouse
tissues by standard phenol chloroform extraction and
ethanol precipitation [68]. Five micrograms of genomic
DNA was then treated with bisulphite reagent for con-
version of unmethylated cytosines of genomic DNA to
uracils as previously described [68]. An aliquot of con-
verted DNA (~100-300 ng) was used for amplification
of the promoters of the Dlc1 6.1 and 6.2 Kb transcripts.
The PCR primers were designed from the regions of the
promoter that do not harbour any CpG dinucleotides
(Table 1, Figure 5A). Primers were designed using PSQ
Assay design software version 1.0.6 (Biotage) and one of
the primer was biotinylated to generate single stranded
DNA which was then sequenced using specific sequen-
cing primers and the Pyromark gold reagent (5× 96
PSQ 96 MA) in Biotage Pyromark Q96 MD machine.
The methylation pattern was analysed using PyroQ-CpG
software version 1.0.0.
Statistical analysis
The one-way analysis of variance (ANOVA) test was used
to compare three different cell lines with respect to the
mean of Dlc1 protein expression, P21
WAF1 protein
expression, focal adhesion frequency, stress fibre fre-
quency and the cell migration rate. Two-way ANOVA
was used to assess the effect of LPA on active Rho induc-
tion in three different cell lines compared to controls.
Correlation between Dlc1 and P21
WAF1 protein expres-
sion was analysed using Pearson correlation test. All the
statistical analysis was performed using Sigma Stat 7 for
Windows software, version 2.03, 1997, SPSS Inc, IL,
USA. Statistical significance was defined as P < 0.05.
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